Erdafitinib
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
Calcipotriol
Vitamin · Antipsoriatic
Also known as calcipotriene
VitaminAntipsoriatic
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
1 major
SEVERE in our sources
PREGNANCY
must be excluded before
FDA category + note
Top interactions
- ErdafitinibSevereDatabaseDDInter
Mechanism
Calcipotriol is a synthetic vitamin D analogue that affects cell division and differentiation in skin cells. It binds to the vitamin D receptor with comparable affinity to calcitriol. Its activity in regulating calcium metabolism is significantly lower than calcitriol, largely due to its pharmacokinetics.
Indications
PsoriasisPlaque PsoriasisPlaque type psoriasis (locally)Skin cancer (systemically, experimental)Immunological disorders (systemically, experimental)Plaque type psoriasis
Dosing
- Adult
- those fed unfortified formula should receive 400 units of vitamin D. However, a larger dose of 3000–4000 units daily often is prescribed. of vitamin D (>10,000 units/day) are not useful in patients with. of 400-800 units/day of vitamin D to frail elderly men and women. (Monier-Faugere et al., 2001).…
Contraindications
- Calcium metabolism disorders
- Generalised pustular or erythrodermic exfoliative psoriasis (use with caution due to enhanced risk of hypercalcaemia)
Side effects
Common
IrritationSkin irritationErythemaScaling
Serious
- Hypercalcaemia (enhanced risk in certain psoriasis types)
- Hypercalcaemia (rare)
Pregnancy & lactation
Pregnancy
must be excluded before
Drug interactions
11 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Other Vitamin drugs
Ask House about Calcipotriol
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-13 · House clinical team